XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)

XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients is a phase 2, randomised interventional study registered as NCT07381777 by Gruppo Oncologico Italiano di Ricerca Clinica, with a registry enrolment figure of 270 participants, started 2026-01-31 and due to reach its primary completion in 2028-07-01. Interventions recorded: XELOX (Capecitabine and Oxaliplatin); Dostarlimab. Conditions listed: Locally Advanced Rectal Cancer (LARC). Primary outcome: Clinical complete response (cCR) at 12 months. Colorectal eligibility wording from the registry: "* Histologically proven rectal adenocarcinoma with distal extension less 16 cm from the anal verge". Sites: Italy. No results are recorded here; the registry entry is the source.